Table 1.

Characteristics of the untreated and ZA-treated groups.

Treatment group	Patients, n	Age, mean (SD)	CCI score, mean (SD)	Docetaxel treatment, n (%)
Untreated	847	68.03 (13.66)	8.88 (1.30)	54 (6.38)
Early ZA-treated	243	64.51 (11.19)	8.49 (0.85)	112 (46.09)
Late ZA-treated	218	66.19 (11.63)	8.60 (0.91)	103 (47.25)
Short ZA persistence	87	66.74 (12.47)	8.63 (1.11)	34 (39.08)
Medium ZA persistence	58	63.78 (11.49)	8.47 (0.71)	25 (43.10)
Long ZA persistence	98	62.96 (9.48)	8.37 (0.63)	53 (54.08)

SD, standard deviation; ZA, zoledronic acid.